NCT05575856

Brief Summary

The study aims to investigate clinically and prognostically relevant parameters in patients with cardiogenic shock within a monocentric observational clinical register.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2019

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2022

Completed
7 months until next milestone

First Posted

Study publicly available on registry

October 12, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

October 12, 2022

Status Verified

October 1, 2022

Enrollment Period

3.5 years

First QC Date

March 12, 2022

Last Update Submit

October 10, 2022

Conditions

Keywords

cardiogenic shockheart failurecardiac arrestshockacute myocardial infarction

Outcome Measures

Primary Outcomes (1)

  • all-cause mortality

    days

    30 days

Secondary Outcomes (3)

  • all-cause mortality

    during hospital stay (up to 30 days)

  • all-cause mortality

    1 years

  • ventilator-free days

    30 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population includes all patients presenting with a cardiogenic shock at the intensive care unit (ICU).

You may qualify if:

  • Cardiogenic shock according to current guidelines

You may not qualify if:

  • other forms of shock not primary associated with cardiac dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Department of Medicine, University Medical Centre Mannheim

Mannheim, 68167, Germany

RECRUITING

Related Publications (5)

  • Rusnak J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Schmitt A, Akin M, Tajti P, Mashayekhi K, Ayoub M, Behnes M, Akin I. Prognostic Influence of Lung Compliance in Patients with Cardiogenic Shock and Invasive Mechanical Ventilation. Rev Cardiovasc Med. 2024 Nov 22;25(11):420. doi: 10.31083/j.rcm2511420. eCollection 2024 Nov.

  • Rusnak J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Forner J, Schmitt A, Akin M, Tajti P, Mashayekhi K, Ayoub M, Akin I, Behnes M. Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac Arrest. Crit Care Med. 2025 Jan 1;53(1):e54-e64. doi: 10.1097/CCM.0000000000006459. Epub 2024 Oct 29.

  • Schupp T, Rusnak J, Forner J, Dudda J, Bertsch T, Behnes M, Akin I. Platelet Count During Course of Cardiogenic Shock. ASAIO J. 2024 Jan 1;70(1):44-52. doi: 10.1097/MAT.0000000000002066. Epub 2023 Oct 12.

  • Behnes M, Rusnak J, Egner-Walter S, Ruka M, Dudda J, Schmitt A, Forner J, Mashayekhi K, Tajti P, Ayoub M, Weiss C, Akin I, Schupp T. Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic Shock. Chest. 2024 Jan;165(1):110-127. doi: 10.1016/j.chest.2023.08.011. Epub 2023 Aug 12.

  • Schmitt A, Schupp T, Rusnak J, Ruka M, Egner-Walter S, Mashayekhi K, Tajti P, Ayoub M, Behnes M, Akin I, Weidner K. Does sex affect the risk of 30-day all-cause mortality in cardiogenic shock? Int J Cardiol. 2023 Jun 15;381:105-111. doi: 10.1016/j.ijcard.2023.03.061. Epub 2023 Mar 31.

MeSH Terms

Conditions

Shock, CardiogenicHeart FailureHeart ArrestShock

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Central Study Contacts

Michael Behnes, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

March 12, 2022

First Posted

October 12, 2022

Study Start

June 1, 2019

Primary Completion

December 1, 2022

Study Completion

December 1, 2023

Last Updated

October 12, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations